|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 103, 806-813, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
V Videm, JL Svennevig, E Fosse, G Semb, A Osterud and TE Mollnes
Complement activation after cardiopulmonary bypass is correlated with
postoperative organ dysfunction. Heparin coating of the entire blood-
contact surface of the cardiopulmonary bypass circuit has proved to reduce
complement activation in vitro. A membrane oxygenator and tubing setup
coated with functionally active heparin was compared with an uncoated,
otherwise identical setup in 20 patients undergoing routine coronary bypass
operations. The concentrations of C3 activation products and the terminal
complement complex were measured in sensitive and specific enzyme
immunoassays. Peak concentrations of C3 activation products were 90.1 (74.7
to 107.4) AU/ml (medians and 95% confidence intervals) and 52.4 (35.7 to
76.4) AU/ml with the uncoated and coated setups, respectively (p = 0.02).
The corresponding concentrations of the terminal complement complex were
26.2 (20.1 to 37.5) AU/ml and 13.7 (11.1 to 25.1) AU/ml (p = 0.03). Blood
loss from the mediastinal drains during the first 12 postoperative hours
was 533 (416 to 975) ml in patients treated with the uncoated setup and 388
(313 to 579) ml in the coated treatment group (p = 0.06) and was
significantly correlated with peak concentrations of the terminal
complement complex (p = 0.01). There were no differences in neutrophil
counts nor platelet numbers between the treatment groups. The approximate
45% reduction in complement activation with the heparin-coated
cardiopulmonary bypass device indicates a substantial improvement of
biocompatibility.
ARTICLES
Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations
University of Oslo Institute for Experimental Medical Research, Norway.
This article has been cited by other articles:
![]() |
E. C. McGee Jr., P. M. McCarthy, and N. Moazami Temporary Mechanical Circulatory Support Card. Surg. Adult, January 1, 2008; 3(2008): 507 - 534. [Full Text] |
||||
![]() |
T. N. Hoel, V. Videm, T. E. Mollnes, K. Saatvedt, F. Brosstad, A. E. Fiane, E. Fosse, and J. L. Svennevig Off-pump cardiac surgery abolishes complement activation Perfusion, July 1, 2007; 22(4): 251 - 256. [Abstract] [PDF] |
||||
![]() |
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Khoshbin, A. E. Dux, H. Killer, A. W Sosnowski, R. K Firmin, and G. J Peek A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators Perfusion, January 1, 2007; 22(1): 15 - 21. [Abstract] [PDF] |
||||
![]() |
S. F Marasco, A. Preovolos, K. Lim, and R. F Salamonsen Thoracotomy in adults while on ECMO is associated with uncontrollable bleeding Perfusion, January 1, 2007; 22(1): 23 - 26. [Abstract] [PDF] |
||||
![]() |
R. Taneja and D. C. Cheng Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372. [Full Text] [PDF] |
||||
![]() |
P. M. Kirshbom, B. E. Miller, K. Spitzer, K. A. Easley, C. E. Spainhour, B. E. Kogon, and K. R. Kanter Failure of surface-modified bypass circuits to improve platelet function during pediatric cardiac surgery. J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 675 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Shann, D. S. Likosky, J. M. Murkin, R. A. Baker, Y. R. Baribeau, G. R. DeFoe, T. A. Dickinson, T. J. Gardner, H. P. Grocott, G. T. O'Connor, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 283 - 290.e3. [Full Text] [PDF] |
||||
![]() |
E. Khoshbin, C. Westrope, S. Pooboni, D. Machin, H. Killer, G. J Peek, A. W Sosnowski, and R. K Firmin Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators Perfusion, May 1, 2005; 20(3): 129 - 134. [Abstract] [PDF] |
||||
![]() |
K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van den Goor, R. Nieuwland, A. van den Brink, W. van Oeveren, P. Rutten, J. Tijssen, and L. Eijsman Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 926 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N Hoel, V. Videm, S. T Baksaas, T. E Mollnes, F. Brosstad, and J. L Svennevig Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery Perfusion, May 1, 2004; 19(3): 177 - 184. [Abstract] [PDF] |
||||
![]() |
T. Ikuta, H. Fujii, T. Shibata, K. Hattori, H. Hirai, H. Kumano, and S. Suehiro A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy Ann. Thorac. Surg., May 1, 2004; 77(5): 1678 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yoshimura, Y. Hiramatsu, Y. Sato, S. Homma, Y. Enomoto, T. Jikuya, and Y. Sakakibara ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation Ann. Thorac. Surg., October 1, 2003; 76(4): 1234 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ninomiya, K. Miyaji, and S. Takamoto Influence of PMEA-coated bypass circuits on perioperative inflammatory response Ann. Thorac. Surg., March 1, 2003; 75(3): 913 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. von Segesser Safety and efficacy of heparin-bonded surfaces in cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(90030): S90 - 91. [Full Text] [PDF] |
||||
![]() |
N. Moazami and P. M. McCarthy Temporary Circulatory Support Card. Surg. Adult, January 1, 2003; 2(2003): 495 - 520. [Full Text] |
||||
![]() |
G. S. Aldea, L. O. Soltow, W. L. Chandler, C. M. Triggs, C. R. Vocelka, G. I. Crockett, Y. T. Shin, W. E. Curtis, and E. D. Verrier Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 742 - 755. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Scholz, R. Solberg, C. Okkenhaug, V. Videm, M. J Gallimore, O. Mathisen, T. E Mollnes, A. Bergan, O. Soreide, G. B Klintmalm, et al. The significance of heparin-coated veno-venous bypass circuits in liver transplantation Perfusion, January 1, 2002; 17(1): 45 - 50. [Abstract] [PDF] |
||||
![]() |
B. Kjaergaard, P. Tolboll, S. Lyduch, and S. Trautner A mobile system for the treatment of accidental hypothermia with extracorporeal circulation Perfusion, December 1, 2001; 16(6): 453 - 459. [Abstract] [PDF] |
||||
![]() |
H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF] |
||||
![]() |
D. A Palanzo, D. L Zarro, N. J Manley, R. M Montesano, M. Quinn, B.-A. Elmore, P. A Gustafson, and J. M Castagna Effect of Carmeda(R) BioActive Surface coating versus TrilliumTM Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass Perfusion, July 1, 2001; 16(4): 279 - 283. [Abstract] [PDF] |
||||
![]() |
T. Scholz, R. Solberg, C. Okkenhaug, V. Videm, M. J Gallimore, O. Mathisen, T. Pedersen, T. E Mollnes, A. Bergan, O. Soreide, et al. Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model Perfusion, July 1, 2001; 16(4): 285 - 292. [Abstract] [PDF] |
||||
![]() |
H. Suhara, Y. Sawa, M. Nishimura, H. Oshiyama, K. Yokoyama, N. Saito, and H. Matsuda Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model Ann. Thorac. Surg., May 1, 2001; 71(5): 1603 - 1608. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. von Segesser Safety and efficacy of heparin-bonded surfaces in cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0200 - 201. [Full Text] [PDF] |
||||
![]() |
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weber, H. P. Wendel, and G. Ziemer Quality Assessment of Heparin Coatings by their Binding Capacities of Coagulation and Complement Enzymes J Biomater Appl, July 1, 2000; 15(1): 8 - 22. [Abstract] [PDF] |
||||
![]() |
Y. Okazaki, Z.-L. Cao, S. Ohtsubo, M. Hamada, K. Naito, K. Rikitake, M. Natsuaki, and T. Itoh Leukocyte-depleted reperfusion after long cardioplegic arrest attenuates ischemia-reperfusion injury of the coronary endothelium and myocardium in rabbit hearts Eur. J. Cardiothorac. Surg., July 1, 2000; 18(1): 90 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Grossi, K. Kallenbach, S. Chau, C. C. Derivaux, M. G. Aguinaga, B. M. Steinberg, D. Kim, S. Iyer, M. Tayyarah, M. Artman, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study Ann. Thorac. Surg., July 1, 2000; 70(1): 191 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Pangburn, K. L. W. Pangburn, V. Koistinen, S. Meri, and A. K. Sharma Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement ,2 J. Immunol., May 1, 2000; 164(9): 4742 - 4751. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-L. Cao, Y. Okazaki, K. Naito, T. Ueno, M. Natsuaki, and T. Itoh Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart Ann. Thorac. Surg., April 1, 2000; 69(4): 1121 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ozawa, K. Yoshihara, N. Koyama, Y. Watanabe, N. Shiono, and Y. Takanashi Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children Ann. Thorac. Surg., February 1, 2000; 69(2): 584 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. K. Fitch, S. Rollins, L. Matis, B. Alford, S. Aranki, C. D. Collard, M. Dewar, J. Elefteriades, R. Hines, G. Kopf, et al. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass Circulation, December 21, 1999; 100(25): 2499 - 2506. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Lazar, Y. Bao, J. Gaudiani, S. Rivers, and H. Marsh Total Complement Inhibition : An Effective Strategy to Limit Ischemic Injury During Coronary Revascularization on Cardiopulmonary Bypass Circulation, September 28, 1999; 100(13): 1438 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wimmer-Greinecker, G. Matheis, S. Martens, G. Oremek, U. Abdel-Rahman, and A. Moritz Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences Eur. J. Cardiothorac. Surg., August 1, 1999; 16(2): 211 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ranucci, A. Mazzucco, R. Pessotto, G. Grillone, V. Casati, L. Porreca, R. Maugeri, M. Meli, P. Magagna, S. Cirri, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial Ann. Thorac. Surg., April 1, 1999; 67(4): 994 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Videm, T. E. Mollnes, E. Fosse, B. Mohr, MD, K. Bergh, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. I. BIOCOMPATIBILITY MARKERS AND DEVELOPMENT OF COMPLICATIONS IN A HIGH-RISK POPULATION J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 794 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Videm, T. E. Mollnes, K. Bergh, E. Fosse, B. Mohr, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. II. MECHANISMS FOR REDUCED COMPLEMENT ACTIVATION IN VIVO J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 803 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Lazar, Y. Bao, S. Rivers, P. R. Treanor, and R. J. Shemin Decreased incidence of arterial thrombosis using heparin-bonded intraaortic balloons Ann. Thorac. Surg., February 1, 1999; 67(2): 446 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Baufreton, M. Moczar, L. Intrator, P. G. Jansen, H. te Velthuis, P. Le Besnerais, J. P. Farcet, C. R. Wildevuur, and D. Y Loisance Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits Perfusion, December 1, 1998; 13(6): 419 - 427. [Abstract] [PDF] |
||||
![]() |
C. Baufreton, M. Kirsch, and D. Y. Loisance Measures to control blood activation during assisted circulation Ann. Thorac. Surg., November 1, 1998; 66(5): 1837 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Edmunds Jr Inflammatory response to cardiopulmonary bypass Ann. Thorac. Surg., November 1, 1998; 66(90050): S12 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Schreurs, M. J. Wijers, Y. J. Gu, W. van Oeveren, R. T. van Domburg, J. H. de Boer, and A. J.J.C. Bogers Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations Ann. Thorac. Surg., July 1, 1998; 66(1): 166 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF] |
||||
![]() |
Y. J. Gu, P. W. Boonstra, A. A. Rijnsburger, J. Haan, and W. van Oeveren Cardiopulmonary Bypass Circuit Treated With Surface-Modifying Additives: A Clinical Evaluation of Blood Compatibility Ann. Thorac. Surg., May 1, 1998; 65(5): 1342 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Lazar, T. Hamasaki, Y. Bao, S. Rivers, S. A. Bernard, and R. J. Shemin Soluble Complement Receptor Type I Limits Damage During Revascularization of Ischemic Myocardium Ann. Thorac. Surg., April 1, 1998; 65(4): 973 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Belboul and N. Al-Khaja Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery Perfusion, December 1, 1997; 12(6): 385 - 391. [Abstract] [PDF] |
||||
![]() |
S. Ashraf, Y. Tian, D. Cowan, A. Entress, P. G. Martin, and K. G. Watterson Release of Proinflammatory Cytokines During Pediatric Cardiopulmonary Bypass: Heparin-Bonded Versus Nonbonded Oxygenators Ann. Thorac. Surg., December 1, 1997; 64(6): 1790 - 1794. [Abstract] [Full Text] |
||||
![]() |
H. t. Velthuis, C. Baufreton, P. G. M. Jansen, C. M. Thijs, C. E. Hack, A. Sturk, C. R. H. Wildevuur, and D. Y. Loisance HEPARIN COATING OF EXTRACORPOREAL CIRCUITS INHIBITS CONTACT ACTIVATION DURING CARDIAC OPERATIONS J. Thorac. Cardiovasc. Surg., July 1, 1997; 114(1): 117 - 122. [Abstract] [Full Text] |
||||
![]() |
H. L. Lazar, X. Zhang, T. Hamasaki, C. A. Memmelo, P. Treanor, S. Rivers, G. S. Aldea, S. A. Bernard, and R. J. Shemin Heparin-Bonded Circuits Decrease Myocardial Ischemic Damage: An Experimental Study Ann. Thorac. Surg., June 1, 1997; 63(6): 1701 - 1705. [Abstract] [Full Text] |
||||
![]() |
S. Bannan, A. Danby, D. Cowan, S. Ashraf, and P. G. Martin Low Heparinization With Heparin-Bonded Bypass Circuits: Is It a Safe Strategy? Ann. Thorac. Surg., March 1, 1997; 63(3): 663 - 668. [Abstract] [Full Text] |
||||
![]() |
A. H. Kuitunen, L. J. Heikkila, and M. T. Salmenpera Cardiopulmonary Bypass With Heparin-Coated Circuits and Reduced Systemic Anticoagulation Ann. Thorac. Surg., February 1, 1997; 63(2): 438 - 444. [Abstract] [Full Text] |
||||
![]() |
H E Hogevold, O Moen, E Fosse, P Venge, J Braten, C Andersson, and T Lyberg Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro Perfusion, January 1, 1997; 12(1): 9 - 20. [Abstract] [PDF] |
||||
![]() |
S. Ashraf, Y. Tian, D. Cowan, U. Nair, R. Chatrath, N. R. Saunders, K. G. Watterson, and P. G. Martin ""Low-Dose"" Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine Release Ann. Thorac. Surg., January 1, 1997; 63(1): 68 - 73. [Abstract] [Full Text] |
||||
![]() |
C. Baufreton, P. Le Besnerais, P. Jansen, J. P. Mazzucotelli, C. R. Wildevuur, and D. Y Loisance Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass Perfusion, November 1, 1996; 11(6): 437 - 443. [Abstract] [PDF] |
||||
![]() |
E. Ovrum, E. A. Holen, G. Tangen, and M.-A. L. Ringdal Heparinized Cardiopulmonary Bypass and Full Heparin Dose Marginally Improve Clinical Performance Ann. Thorac. Surg., October 1, 1996; 62(4): 1128 - 1133. [Abstract] [Full Text] |
||||
![]() |
M. Yii, T. Gourlay, J. Fleming, B. Matata, and K. Taylor Evaluation of Carmeda(R) Bioactive Surface (CBAS(R)), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass Perfusion, May 1, 1996; 11(3): 229 - 240. [PDF] |
||||
![]() |
L. K von Segesser Surface coating of cardiopulmonary bypass circuits Perfusion, May 1, 1996; 11(3): 241 - 245. [PDF] |
||||
![]() |
P. G. M. Jansen, C. Baufreton, P. Le Besnerais, D. Y. Loisance, and C. R. H. Wildevuur Heparin-Coated Circuits and Aprotinin Prime for Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 1996; 61(5): 1363 - 1366. [Abstract] [Full Text] |
||||
![]() |
R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084. [Abstract] [Full Text] |
||||
![]() |
H. t. Velthuis, P. G. M. Jansen, C. E. Hack, L. Eijsman, and C. R. H. Wildevuur Specific Complement Inhibition With Heparin-Coated Extracorporeal Circuits Ann. T |